IP Library Granted Patent US 9,381,226
Granted Patent B2
US 9,381,226 · App. 12/526,071 · Granted Jul 5, 2016

Methods and compositions related to inhibition of viral entry

Inventors: Michael S. Kay (Salt Lake City, UT); Brett D. Welch (Salt Lake City, UT)
Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
A61K38/10A61K47/481A61K47/48215A61K47/48253C07K5/1024C07K7/06G01N33/5008G01N33/56983G01N2333/005G01N2333/162G01N2500/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,226
App. No.
12/526,071
Granted
Jul 5, 2016
Kind
B2
Abstract

Disclosed are compositions and methods for inhibiting viral entry.

Claims (13)

1. An isolated composition comprising at least one peptide that interacts with the N-trimer pocket of a viral transmembrane protein wherein the at least one peptide comprises the amino acid sequence of SEQ ID NO: 36.

2. The composition of claim 1 , wherein the at least one peptide is linked to at least one other peptide.

3. The composition of claim 2 , wherein a crosslinker is used to multimerize the peptides.

4. The composition of claim 3 , wherein the crosslinker is PEG.

5. The composition of claim 2 , wherein the peptides are crosslinked into branched structures.

6. The composition of claim 2 , wherein the N-termini of the peptides are crosslinked.

7. The composition of claim 2 , wherein the C-termini of the peptides are crosslinked.

8. The composition of claim 2 , wherein the N-terminus of one peptide and the C-terminus of the other peptide are crosslinked.

9. The composition of claim 1 , wherein the viral transmembrane protein is HIV gp41.

10. The composition of claim 1 , wherein the at least one peptide is selected from any one of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 12, 13, 23, 24, 25, 26, 27, 28, 29, or a fragment thereof.

11. The composition of claim 1 , wherein the composition inhibits viral entry into a cell.

12. The composition of claim 1 , wherein at least one peptide is a D-peptide.

13. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 11, 2015
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035624/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2010
From: KAY, MICHAEL S.; WELCH, BRETT D.
To: UNIVERSITY OF UTAH
Reel/Frame 023896/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2010
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 023896/0383 →
Continuity (2)
Provisional Application 60888944 · Feb 8, 2007
Related Publication 20100184663A1 · Jul 22, 2010